Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival

Breast Cancer Research and Treatment

Volumn 147, Issue 2, 2014, Pages 381-387

  Pande, Mala ^a   Bondy, Melissa L ^b   Do, Kim Anh ^a   Sahin, Aysegul A ^a   Ying, Jun ^a   Mills, Gordon B ^a   Thompson, Patricia A ^c   Brewster, Abenaa M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Breast cancer; Disease free survival; PI3 K AKT mTOR pathway; Prognosis; Single nucleotide polymorphisms

Indexed keywords

MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

BREAST TUMOR; CANCER STAGING; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; OBESITY; PATHOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OBESITY; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84939877332     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3081-9     Document Type: Article

References (35)

1. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988–1004
2. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64(1):9–29
3. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18(16):1926–1945
4. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N (2006) mTOR, translation initiation and cancer. Oncogene 25(48):6416–6422
5. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4(5):335–348
6. Dutcher JP (2004) Mammalian target of rapamycin inhibition. Clin Cancer Res 10(18 Pt 2):6382S–6387S
7. Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395–402
8. Chandarlapaty S, Sakr RA, Giri D et al (2012) Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 18(24):6784–6791
9. Karlsson E, Perez-Tenorio G, Amin R et al (2013) The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res 15(5):R96
10. Kirkegaard T, Witton CJ, McGlynn LM et al (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207(2):139–146
11. Lu CH, Wyszomierski SL, Tseng LM et al (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13(19):5883–5888
12. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117–127
13. Razis E, Bobos M, Kotoula V et al (2011) Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat 128(2):447–456
14. Tevaarwerk AJ, Gray RJ, Schneider BP et al (2013) Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119(6):1140–1148
15. Chen M, Gu J, Delclos GL et al (2010) Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31(8):1387–1391
16. Sun CH, Chang YH, Pan CC (2011) Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58(7):1054–1063
17. Yoshioka A, Miyata H, Doki Y et al (2008) The activation of Akt during preoperative chemotherapy for esophageal cancer correlates with poor prognosis. Oncol Rep 19(5):1099–1107
18. Brewster AM, Do KA, Thompson PA et al (2007) Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 25(28):4438–4444
19. Carlson CS, Eberle MA, Rieder MJ et al (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74(1):106–120
20. Thorisson GA, Smith AV, Krishnan L, Stein LD (2005) The international hapmap project web site. Genome Res 15(11):1592–1593
21. QIAamp® DNA Mini and Blood Mini Handbook (2010) QIAGEN
22. Applied Biosystems® Arcturus® PicoPure® DNA Extraction Kit (2010)
23. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc 57:289–300
24. Diorio C, Brisson J, Berube S, Pollak M (2008) Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17(4):880–888
25. Gu F, Schumacher FR, Canzian F et al (2010) Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev 19(11):2877–2887
26. Siddle K (2011) Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 47(1):R1–R10
27. Davison Z, de Blacquiere GE, Westley BR, May FE (2011) Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 13(6):504–515
28. Zhang Y, Moerkens M, Ramaiahgari S et al (2011) Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 13(3):R52
29. Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11(6):530–542
30. Hartog H, Boezen HM, de Jong MM et al (2013) Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer. Breast 22(6):1155–1160
31. Pasanisi P, Venturelli E, Morelli D et al (2008) Serum insulin-like growth factor-I and platelet-derived growth factor as biomarkers of breast cancer prognosis. Cancer Epidemiol Biomarkers Prev 17(7):1719–1722
32. Mahadevan D, Sutton GR, Arteta-Bulos R et al (2014) Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies. Cancer Chemother Pharmacol 73(3):467–473
33. Khan S, Shukla S, Sinha S, Meeran SM (2013) Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev 24(6):503–513
34. Chen X, Xiang YB, Long JR et al (2012) Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer 118(13):3356–3364
35. Teras LR, Goodman M, Patel AV et al (2009) No association between polymorphisms in LEP, LEPR, ADIPOQ, ADIPOR1, or ADIPOR2 and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 18(9):2553–2557